Related Experiment Video
Updated: Jul 16, 2026
06:51
Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy
Published on: December 17, 2019
[Treatment of aggressive lymphomas]
B Gleissner1, C Zwick, M Pfreundschuh
1Medizinische Klinik I, Universitätsklinikum Saarland, Kirrberger Strasse, 66421, Homburg, Deutschland.
Der Internist
|March 16, 2007
Summary
Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy shows high survival for younger aggressive lymphoma patients with good prognosis. However, those with poorer risk profiles require improved treatment strategies.
Area of Science:
- Hematology
- Oncology
- Clinical Trials
Context:
- The age-adjusted International Prognostic Index (IPI) stratifies risk in aggressive lymphoma patients.
- Younger patients (< or = 60 years) with aggressive lymphomas benefit from risk-based treatment stratification.
- Current R-CHOP-21 regimens show differential efficacy based on IPI scores and disease bulk.
Purpose:
- To evaluate the efficacy of R-CHOP-21 in younger aggressive lymphoma patients across different IPI risk groups.
- To identify subgroups of patients who may require more intensive or alternative therapeutic approaches.
- To review established treatment protocols for older patients (> 60 years) with aggressive lymphomas.
Summary:
- R-CHOP-21 achieves >90% 3-year event-free survival in younger aggressive lymphoma patients with very good prognosis (IPI 0, no bulk).
- Patients with less favorable risk profiles (IPI 1, or IPI 0 with bulk) have <80% 3-year event-free survival with R-CHOP-21.
- Younger patients with worse risk profiles have a 5-year survival of 60%, necessitating dose-dense regimens or stem cell transplantation in trials.
- For patients >60 years, R-CHOP-14 followed by additional rituximab demonstrates optimal outcomes across all IPI groups.
Impact:
- Highlights the need for improved therapeutic strategies for younger aggressive lymphoma patients with adverse prognostic factors.
- Supports the continued investigation of dose-dense regimens and autologous stem cell transplantation for high-risk young patients.
- Reinforces the established benefit of R-CHOP-14 in older aggressive lymphoma patients, irrespective of IPI score.
Related Concept Videos
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...